Moderna’s COVID vaccine is driving growth again. The stock is down anyway.

Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April ...
Nasdaq

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...